Kura Oncology (NASDAQ:KURA) Shares Down 8.1% – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA) traded down 8.1% during trading on Monday . The stock traded as low as $9.52 and last traded at $9.3720. 305,897 shares traded hands during trading, a decline of 80% from the average session volume of 1,525,224 shares. The stock had previously closed at $10.20.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Lake Street Capital assumed coverage on Kura Oncology in a report on Tuesday, April 14th. They set a “buy” rating and a $23.00 price objective for the company. Mizuho cut their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Wedbush cut their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Finally, Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $25.90.

Kura Oncology Stock Performance

The firm has a market cap of $832.66 million, a PE ratio of -2.80 and a beta of 0.36. The company has a 50 day simple moving average of $9.19 and a 200-day simple moving average of $9.47. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. As a group, equities research analysts anticipate that Kura Oncology, Inc. will post -3.51 EPS for the current year.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp lifted its position in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC lifted its position in Kura Oncology by 111.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after purchasing an additional 965,256 shares during the last quarter. AQR Capital Management LLC lifted its position in Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after purchasing an additional 820,020 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its position in Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.